Tag Archives: Dr Oystein Fluge

Cancer doctor Dagfinn Øgreid has treated ME patients with rituximab

Posted on 11/26/2015 by wames

Blog article: Offers private ME treatment with cancer drugs – scientists react, by Anne Grete Storvik, Nov 23 2015 in Dagensmedicin [ translated by Google translate] A private clinic in Sandnes offers treatment for ME with the cancer drug rituximab. Patients pay … Continue reading →

Posted in News | Tagged , , , , , , | 1 Comment

UK rituximab trial fundraising total almost reached

Posted on 09/28/2015 by wames

Invest in ME has announced the latest fundraising total for the rituximab/B-cell research, which is a great boost as the research team at UCL are about to visit and discuss the subject with Dr Fluge and Professor Mella in Haukeland University Hospital, … Continue reading →

Posted in News | Tagged , , , , , , , | Comments Off on UK rituximab trial fundraising total almost reached

Elevated autoantibodies found in CFS subgroup

Posted on 09/28/2015 by wames

Research highlights: β adrenergic and muscarinic acetylcholine receptor autoantibodies are elevated in a subset of patients with Chronic Fatigue Syndrome (CFS). Elevated autoantibodies in CFS correlate with elevated IgG1-3 subclass levels, thyreoperoxidase and ANA antibodies and T cell activation. In … Continue reading →

Posted in News | Tagged , , , , , , , | Comments Off on Elevated autoantibodies found in CFS subgroup

Rituximab leads to B-cell depletion and remission in ME/CFS

Posted on 07/02/2015 by wames

Research abstract: Background: Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We previously reported a pilot case series followed by a small, randomized, placebo-controlled phase II study, suggesting that B-cell depletion using the monoclonal anti-CD20 antibody rituximab … Continue reading →

Posted in News | Tagged , , , , , | Comments Off on Rituximab leads to B-cell depletion and remission in ME/CFS

Fluge & Mella’s patent application for a CFS treatment

Posted on 04/02/2015 by wames

Excerpt from patent application: Inventors: Øystein Fluge & Olav Mella Date of publication 26 11 2014 Nitric oxide donor for the treatment of chronic fatigue syndrome. Description [0001] The present invention relates in a first aspect to a nitric oxide donor for … Continue reading →

Posted in News | Tagged , , , , | Comments Off on Fluge & Mella’s patent application for a CFS treatment

Rituximab interviews

Posted on 04/02/2015 by wames

Two Norwegian scientists, Øystein Fluge and Olav Mella, who have been researching the effects of an anti-lymphoma drug called Rituximab on people with ME/CFS, talked about their work on the BBC Radio Cambridgeshire programme ‘Naked Scientists’ on Sunday, 22 March. … Continue reading →

Posted in News | Tagged , , , , , , , , , , , , , | Comments Off on Rituximab interviews

Norwegian Rituximab trial update

Posted on 08/26/2014 by wames

The Norwegian multicenter Rituximab study begins The long-awaited Norwegian phase III study of Rituximab as a treatment for ME/CFS is now getting off the ground. The study is led by the oncologists Prof Olav Mella and Dr Øystein Fluge at … Continue reading →

Posted in News | Tagged , , , , , | Comments Off on Norwegian Rituximab trial update

Update on rituximab

Posted on 04/01/2012 by wames

Drs Oystein Fluge and Olav Mella have been given 2 million Norwegian Kroners (approx. £220,000) to help fund a larger multi-centre follow-up study to confirm their findings  that some people with ME had benefited from the immune modulator rituximab. This … Continue reading →

Posted in News | Tagged , , | Comments Off on Update on rituximab